ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
당뇨병성 신장 질환 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 6.0%를 나타낼 것으로 예측되고 35억 3,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 맞춤형 의약품 및 바이오마커 개발, 전 세계 당뇨병 발병률 증가, 질병 수정 치료법 주력, 텔레헬스 및 원격 치료, 의료 정책 및 보험 적용 범위 변화 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 신대체요법의 발전, 정밀의학 접근법, 조기 발견 및 진단에 주력, 치료제 발전, 동반질환 관리 증가 등이 포함됩니다.
향후 5년간 6.0% 성장 전망은 이전 예측 대비 0.1% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 인상으로 영국 및 일본산 SGLT2 억제제와 신성빈혈 의약품 비용이 촉진되어 미국 신장학 진료에 부담이 가중되고, 만성 신장병 관리 비용이 악화될 전망입니다. 상호 보복 관세와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 될 것입니다.
만성 신장 질환의 유병률 증가는 당뇨병성 신장 질환 시장 성장을 촉진할 것으로 예상됩니다. 만성 신장 질환(CKD)은 신장 기능이 점진적으로 상실되는 장기 질환으로, 고혈압, 빈혈, 골질환 등 다양한 합병증을 유발합니다. 만성 신장 질환 치료에는 진단 및 치료 옵션이 필요하며, 이는 궁극적으로 당뇨병성 신장 질환 시장 확장을 촉진합니다. 예를 들어, 2023년 6월 영국 주요 자선 단체인 신장 연구 영국(Kidney Research UK)은 만성 신장 질환이 영국 인구의 10% 이상인 약 720만 명에게 영향을 미친다고 보고했습니다. 이 중 325만 명은 가장 심각한 단계에 있으며, 약 390만 명은 초기 단계로 종종 치료받지 않고 무증상입니다. 예측에 따르면 영국 내 만성 신장 질환 총 환자 수는 2033년까지 761만 명으로 증가할 수 있습니다. 따라서 만성 신장 질환의 증가하는 유병률은 당뇨병성 신장 질환 시장 성장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 당뇨병성 신장 질환 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 당뇨병성 신장 질환 시장 : 성장률 분석
세계의 당뇨병성 신장 질환 시장 실적 : 규모와 성장(2019-2024년)
세계의 당뇨병성 신장 질환 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 당뇨병성 신장 질환 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 당뇨병성 신장 질환 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
1형 당뇨병
2형 당뇨병
세계의 당뇨병성 신장 질환 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안지오텐신 수용체 차단제(ARB)
안지오텐신 전환효소(ACE) 억제제
항산화 염증 조절제
칼슘 채널 차단제
기타 치료법
세계의 당뇨병성 신장 질환 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
홈케어
전문센터
기타 최종 사용자
세계의 당뇨병성 신장 질환 시장, 1형 당뇨병 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
자가면역 관련 당뇨병성 신장 질환
조기 발병 당뇨병성 신장 질환
세계의 당뇨병성 신장 질환 시장, 2형 당뇨병 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
비만 관련 당뇨병성 신장 질환
후기 발병 당뇨병성 신장 질환
제7장 지역별 및 국가별 분석
세계의 당뇨병성 신장 질환 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 당뇨병성 신장 질환 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
당뇨병성 신장 질환 시장 : 경쟁 구도
당뇨병성 신장 질환 시장 : 기업 프로파일
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Fresenius SE & Co. KGaA
F. Hoffmann-La Roche AG
Abbott Laboratories
Reata Pharmaceuticals Inc.
Merck & Co.
Mitsubishi Tanabe Pharma Corporation
Johnson & Johnson pvt. Ltd.
Eli Lilly and Company
GlaxoSmithKline plc
AbbVie Inc.
Boehringer Ingelheim International GmbH
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
당뇨병성 신장 질환 시장(2029년) : 새로운 기회를 제공하는 국가
당뇨병성 신장 질환 시장(2029년) : 새로운 기회를 제공하는 부문
당뇨병성 신장 질환 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Diabetic kidney disease is a form of renal disease resulting from complications of diabetes, where elevated blood sugar levels lead to kidney damage. The kidneys' blood vessels can be adversely affected by high blood glucose, reducing their functionality.
The primary types of diabetic kidney disease are associated with both type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition characterized by minimal or no insulin production by the pancreas. This deficiency leads to elevated blood sugar levels, causing damage to the nephrons and renal blood vessels. Managing blood sugar levels in type 1 diabetes often requires daily insulin injections. Treatment for diabetic kidney disease includes interventions such as angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other medical approaches provided in facilities such as hospitals, homecare, specialty centers, and more.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The diabetic kidney disease market research report is one of a series of new reports from The Business Research Company that provides diabetic kidney disease market statistics, including global market size, regional shares, competitors with a diabetic kidney disease market share, detailed diabetic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. This diabetic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The diabetic kidney disease market size has grown steadily in recent years. It will grow from $2.67 billion in 2024 to $2.8 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to early understanding of diabetes complications, advancements in diagnostic techniques, development of ace inhibitors and arbs, clinical trials and treatment protocols, guidelines and disease management protocols.
The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to $3.53 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine and biomarker development, rising global diabetes incidence, focus on disease modification therapies, telehealth and remote care, healthcare policy and reimbursement changes. Major trends in the forecast period include advancements in renal replacement therapies, precision medicine approach, focus on early detection and diagnosis, therapeutic advancements, rise in comorbidities management.
The forecast of 6.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. nephrology practices by driving up the cost of SGLT2 inhibitors and renal anemia drugs sourced from the UK and Japan, exacerbating chronic kidney disease management expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of chronic kidney disease is anticipated to drive the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) is a long-term condition that leads to a gradual loss of kidney function, resulting in various complications such as high blood pressure, anemia, and bone diseases. Treating chronic kidney diseases necessitates diagnostic and treatment options, which ultimately fuels the expansion of the diabetic kidney disease market. For instance, in June 2023, Kidney Research UK, a prominent charity in the UK, reported that chronic kidney disease affects approximately 7.2 million people in the United Kingdom, representing over 10% of the population. Among these individuals, 3.25 million are in the most severe stages of the disease, while around 3.9 million are in the early stages, which are often untreated and asymptomatic. Projections suggest that the total number of individuals with chronic kidney disease in the United Kingdom could rise to 7.61 million by 2033. Thus, the increasing prevalence of chronic kidney disease is propelling the growth of the diabetic kidney disease market.
The growing healthcare expenditure is expected to enhance the growth of the diabetic kidney disease market in the future. Healthcare expenditure refers to the total funds allocated for healthcare-related goods and services within a specific timeframe, typically at a national or institutional level. Increased healthcare spending promotes the adoption of advanced diagnostic technologies, enabling early and accurate detection of diabetic kidney disease and facilitating timely intervention and treatment. For example, in May 2023, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth rate of 0.9% in 2022. The UK healthcare expenditure was approximately £292 billion in 2023. Therefore, the rising healthcare expenditure is driving the growth of the diabetic kidney disease market.
Technological advancements emerge as a pivotal trend gaining traction in the diabetic kidney disease market. Companies within this sector embrace novel technologies to fortify their market standing. For instance, in August 2022, Bloom Diagnostics, a US-based organization specializing in diagnostics and healthcare devices, introduced the Bloom Kidney Test. Integrated with the Bloom Smart System, this diagnostic tool evaluates kidney health by measuring cystatin C levels-a reliable indicator of kidney function. Categorizing kidney function into three stages-normal, mildly decreased, and decreased-the Bloom Kidney Test leverages cloud-based algorithms and AI technology within the Bloom Smart System. This integration combines test outcomes with pertinent health data such as medical history, lifestyle, and patient symptoms, facilitating comprehensive analysis and management.
Leading companies in the diabetic kidney disease market are actively innovating by developing new products such as medications tailored for chronic kidney disease (CKD), aiming for wider customer reach, increased sales, and revenue growth. These medications for CKD primarily focus on symptom management, slowing disease progression, and addressing complications arising from impaired kidney function. For instance, Bayer AG, a Germany-based pharmaceutical company, introduced Kerendia in August 2022-a medication specifically designed to manage CKD associated with diabetes. Kerendia stands out as a non-steroidal, selective mineralocorticoid receptor antagonist, uniquely tailored for individuals with chronic kidney disease linked to type-II diabetes. Offering a distinctive treatment approach, Kerendia holds promise in slowing CKD progression and reducing the risk of kidney failure in this susceptible patient group.
In January 2023, AstraZeneca, a UK-based biotech and pharmaceutical giant, finalized the acquisition of Cincor Pharma Inc. for an undisclosed sum. This strategic move strengthens AstraZeneca's cardiorenal pipeline by integrating CinCor's baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) aimed at lowering blood pressure in treatment-resistant hypertension. Cincor Pharma Inc., a US-based biopharmaceutical company, specializes in developing drugs for kidney disease management. AstraZeneca's acquisition bolsters its portfolio by incorporating innovative solutions such as baxdrostat, further solidifying its position in addressing cardiorenal complications and advancing therapeutic options for kidney disease management.
Major companies operating in the diabetic kidney disease market include AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited
North America was the largest region in the diabetic kidney disease market in 2024. The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the diabetic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The diabetic kidney disease market includes revenues earned by entities by providing diabetic kidney disease treatments for kidney stones, kidney infection, polycystic kidney disease, and kidney cysts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diabetic Kidney Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diabetic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for diabetic kidney disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic kidney disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Type 1 Diabetes; Type 2 Diabetes
2) By Treatment: Angiotensin Receptor Blockers (Arbs); Angiotensin-Converting Enzyme (Ace) Inhibitors; Antioxidant Inflammation Modulator; Calcium Channel Blockers; Other Treatments
3) By End User: Hospitals; Homecare; Specialty Centers; Other End Users
Subsegments:
1) By Type 1 Diabetes: Autoimmune-Related Diabetic Kidney Disease; Early-Onset Diabetic Kidney Disease
2) By Type 2 Diabetes: Obesity-Related Diabetic Kidney Disease; Late-Onset Diabetic Kidney Disease
Companies Mentioned: AstraZeneca plc; Pfizer Inc.; Novartis AG; Bayer AG; Sanofi SA; Teva Pharmaceutical Industries Ltd.; Bristol-Myers Squibb Company; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Ltd.; Fresenius SE & Co. KGaA; F. Hoffmann-La Roche AG; Abbott Laboratories; Reata Pharmaceuticals Inc.; Merck & Co.; Mitsubishi Tanabe Pharma Corporation; Johnson & Johnson pvt. Ltd.; Eli Lilly and Company; GlaxoSmithKline plc; AbbVie Inc.; Boehringer Ingelheim International GmbH; Chugai Pharmaceutical Co. Ltd.; Daiichi Sankyo Company Limited
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Diabetic Kidney Disease Market Characteristics
3. Diabetic Kidney Disease Market Trends And Strategies
4. Diabetic Kidney Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Diabetic Kidney Disease Growth Analysis And Strategic Analysis Framework
5.1. Global Diabetic Kidney Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Diabetic Kidney Disease Market Growth Rate Analysis
5.4. Global Diabetic Kidney Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Diabetic Kidney Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Diabetic Kidney Disease Total Addressable Market (TAM)
6. Diabetic Kidney Disease Market Segmentation
6.1. Global Diabetic Kidney Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 1 Diabetes
Type 2 Diabetes
6.2. Global Diabetic Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin Receptor Blockers (Arbs)
Angiotensin-Converting Enzyme (Ace) Inhibitors
Antioxidant Inflammation Modulator
Calcium Channel Blockers
Other Treatments
6.3. Global Diabetic Kidney Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Speciality Centres
Other End Users
6.4. Global Diabetic Kidney Disease Market, Sub-Segmentation Of Type 1 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autoimmune-Related Diabetic Kidney Disease
Early-Onset Diabetic Kidney Disease
6.5. Global Diabetic Kidney Disease Market, Sub-Segmentation Of Type 2 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Obesity-Related Diabetic Kidney Disease
Late-Onset Diabetic Kidney Disease
7. Diabetic Kidney Disease Market Regional And Country Analysis
7.1. Global Diabetic Kidney Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Diabetic Kidney Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
